Company Filing History:
Years Active: 2021
Title: Rike Nabbefeld: Innovative Contributions in Nanotechnology
Introduction: Rike Nabbefeld, based in Cologne, Germany, is a distinguished inventor with a notable patent in the field of nanotechnology. His work at Evonik Operations GmbH has led to significant advancements in the development of nanoparticles, which have various potential applications in the biomedical sector.
Latest Patents: Nabbefeld holds a patent for a nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer, and an acylated human lactoferrin-derived peptide. This innovative nanoparticle features a core that includes a bio-resorbable polyester combined with a hydrophilic polymer. The special acylated human lactoferrin-derived peptide that coats the core offers unique properties, with the peptide's amino acid sequence identified as SEQ ID NO. 1: KCFQWQRNMRKVRGPPVSCIKR, or variants that differ by no more than 8 amino acid positions from this sequence. The N-terminus of the peptide is acylated with a C-monoacyl group, making this invention particularly valuable for applications requiring biocompatibility.
Career Highlights: Rike Nabbefeld has dedicated his career to exploring innovative solutions in materials science. His current role at Evonik Operations GmbH enables him to apply his expertise to develop cutting-edge technologies that address modern challenges in healthcare and materials development.
Collaborations: Throughout his career, Nabbefeld has collaborated with notable colleagues such as Roland Brock and Silko Grimm. These collaborations foster an environment of innovation and creativity, leading to the continuous development of new technologies and processes within the company.
Conclusion: Rike Nabbefeld represents a new generation of inventors making impactful contributions to nanotechnology. His work at Evonik Operations GmbH not only showcases his innovative mindset but also holds the promise of advancing biomedical applications through the development of unique nanoparticle formulations. His patent stands as a testament to the importance of collaboration and research in driving innovation forward.